
Elicera Q2 - Developing CARMA – Data strengthens ELC-301 outlook

Redeye returns with an updated view following Elicera's Q2 report and encouraging data from the phase I /II CARMA study, evaluating ELC-301 in diffuse large B-cell lymphoma (DLBCL). In light of the new data, we raise our likelihood of approval (LoA) assumptions for ELC-301 and make minor positive commercial adjustments, resulting in a higher valuation range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Elicera Q2 - Developing CARMA – Data strengthens ELC-301 outlook